Data from the IMPRESS study 1,2
AIM: To compare resource use in the 6 and 12 months before and after rifaximin- α initiation in UK patients with HE. This study was sponsored by Norgine.
Adapted from Hudson et al. 2017
- 4% patients (9/145) reported adverse drug reactions(ADRs)
- 4 of these 9 patients had C difficile infection, but none discontinued treatment
- No serious ADRs were reported